Woman faces more than $20,000 in medical bills after wild bat flies into her mouth
In August last year, Erica Kahn, 33, was taking photos of the sky in Arizona when a bat got stuck between her head and the camera, and partially entered her mouth as she screamed, according to KFF Health News.
Her doctor father urged her to get a number of rabies vaccinations, even though Kahn doesn't believe the bat bit her. She told the outlet she had recently been forced to leave her biomedical engineering job and purchased a health insurance policy online the day after the bat flew into her mouth to help with the treatments in Arizona, Massachusetts, and Colorado.
But the insurance company rejected paying for the treatments and pointed to a 30-day waiting period.
Kahn believed she would be covered as long as she got insurance before going to the hospital in Flagstaff, Arizona, noting that she called the company before she bought the policy and that she was told services connected to an accident or 'life-threatening' emergency would be covered.
'The required waiting period for this service has not been met,' said the company. After being treated at four different treatment centers, she faced bills of $20,749.
'I thought it must have been a mistake,' she told KFF. 'I guess I was naive.'
The outlet noted that Kahn has since acquired a new job, negotiated down one of the bills, put in place a payment plan for another, and is in the appeals process for the rest.
She said she regrets allowing gaps in her healthcare coverage after she lost her job.
'That's a very big lesson I learned the hard way,' said Kahn, who still looks back at the incident with a sense of humor.
'I know what bats taste like now. It's an earthy, sweet kind of flavor,' she told KFF.
'It's actually a pretty funny story — if it weren't for the horrible medical bill that came with it.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
CellCentric to Participate in Upcoming Investor Conferences
Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - August 5, 2025) - CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences. These events provide an opportunity to engage with the investment community and highlight the company's clinical progress with inobrodib, which will be entering a potentially registration enabling study later this year. Upcoming appearances include: Oppenheimer & Co.'s 2025 Biotech in the Berkshires, Berkshires, MAPresentation time: Tuesday, August 5, 2025, 11:51am ET Citi's 2025 Biopharma Back to School Conference, Boston, MA1x1s only: Tuesday, September 2, 2025 2025 Wells Fargo Healthcare Conference, Boston, MAPresentation time: September 3, 10:15am ET Cantor Global Healthcare Conference, New York, NY1x1s only: September 4, 2025 Morgan Stanley Health Care Conference, New York, NYPresentation time: September 8, 2025, 3:20pm ET BofA Securities Healthcare Trailblazers Private Company Conference, Boston, MA1x1s only: September 17, 2025 For more information or to request a meeting, please contact: IR@ About inobrodib Inobrodib is a potential new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, including MYC and IRF4. It has been evaluated in over 400 patients to date and has a favourable safety and tolerability profile. Clinical activity has been seen in multiple settings, both solid tumour and hematologic malignancies. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. Its differentiated profile may broaden use among patients who cannot tolerate or access other treatments, while its ease of administration could reduce healthcare system burden relative to more complex therapies. About CellCentricCellCentric is a privately held biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. Inobrodib is in a Phase II clinical trial for patients with relapsed/refractory multiple myeloma, with additional indications under consideration. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. Headquartered in the UK with expanding U.S. operations, CellCentric is backed by a global syndicate of life science investors, including RA Capital, Forbion (including ForCal), Morningside, Pfizer Ventures, Avego, and the American Cancer Society's BrightEdge Fund. For more information, please visit: To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Vertex plan to build on pain drug breakthrough hits hurdles
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals made its name and fortune by developing ever more effective medicines for the rare disease cystic fibrosis. On Monday, the biotechnology company disclosed two setbacks that suggest one of its next targets for a similarly iterative approach to innovation, pain, may not go as smoothly as it and investors had hoped. Alongside earnings for the second quarter, Vertex disclosed that a successor drug to its pioneering pain medicine Journavx, which was approved this January in the U.S., failed to meet its main goal in a mid-stage clinical trial. As a result, Vertex will no longer advance this follow-on compound, dubbed VX-993, into pivotal testing for acute pain treatment on its own. At the same time, Vertex informed investors it would not start a late-stage study of Journavx in a form of sciatica, after the Food and Drug Adminsitration indicated an expanded approval in peripheral neuropathic pain would be unlikely. The company had aimed to use data from testing in sciatica and an ongoing study in diabetic neuropathy to widen Journavx's use beyond the acute pain indication it currently holds. 'While a broad [peripheral neuropathic pain] label remains our goal, at this time the FDA does not see a path to a broad indication as such,' said CEO Reshma Kewalramani on a Monday evening call with investors. Instead, Vertex will start a second Phase 3 trial in diabetic neuropathy to eventually support an approval application there. According to estimates recently cited by Vertex, about 2.4 million people in the U.S. have diabetic neuropathy — about one-fifth the 11 million or so people who have peripheral neuropathic pain, which includes sciatica and other types of chronic nerve pain. Shares in Vertex fell by more than 14% in post-market trading Monday on the news, which, if sustained, would translate to erasure of about $17 billion in market capitalization. Pain is one of many research directions Vertex is pursuing as it seeks to become bigger than the cystic fibrosis medicines that made it one of biotech's most valuable companies. But it's arguably the company's highest profile bet, as Journavx offers an alternative to the powerful, but dangerously addictive opioid painkillers that have claimed hundreds of thousands of lives in the U.S. Journavx works differently, in ways that are not thought to be similarly habit-forming. While the medicine proved effective at dulling the sharp and stabbing pain that can occur after surgeries like a bunion removal or 'tummy tuck,' data from testing showed it to be about as potent as a weak opioid. Still, analysts have penciled in billions of dollars for future Journavx sales, seeing a large market in post-surgery therapy that could later be expanded to include chronic pain treatment. Getting to that goal now looks like it will require more time and more testing. Vertex aims to finish enrolling both diabetic neuropathy studies by the end of next year and intends to keep engaging the FDA on paths toward an expansive peripheral neuropathic pain label. In a note to clients, RBC Capital Markets analyst Brian Abrahams said Monday's update eliminates a 'blue sky' scenario for Vertex. The study failure for VX-993, meanwhile, weakens Vertex's argument that the company can improve on Journvax's effectiveness with successive compounds, as it did in cystic fibrosis. The news, Abrahams wrote, 'reduces any potential halo effect around the pain franchise and underscores that it may be more challenging than some expected to iterate and improve upon [Journavx].' Paul Matteis, an analyst at Stifel, told his bank's clients in a separate note that VX-993's failure hints Vertex 'may have nearly maximized the efficacy' it can extract from the way Journavx works, which is by blocking pain-regulating proteins known as NaV1.8. Kewalramani acknowledged that possibility on Monday's call. 'The outcome of the study combined with the totality of evidence from our preclinical models and previous NaV1.8 inhibitor clinical studies in acute pain suggest we are at the high end of the NaV1.8 dose response curve for acute pain in the post-bunionectomy setting.' Vertex continues to enroll a Phase 2 study testing VX-993 in diabetic neuropathic pain. And it could still combine the compound with other molecules that target a related protein called NaV1.7. Yet the setbacks mean investor focus will fall more squarely on Journavx's performance on the market. There, Vertex reported $12 million in sales during the three-month period between April and June, beating Wall Street forecasts by several million dollars. More than 111,000 prescriptions have been written for the drug since it became available at pharmacies in early March, Vertex said. Recommended Reading A new, non-opioid pain drug is here. Getting it to patients could be agony. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series
WATERTOWN, Mass., August 05, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. "HCW@Home" series. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at or by registering here. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing Hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. View source version on Contacts Media and Investors Contact: Jennifer Viera617-744-3848jviera@
